Date of Publication: 22-May-2026
INTELLIGENCE OVERVIEW
Agency: Bhutan FDA
The Bhutan Food and Drug Authority (BFDA) has released a draft guideline on the Importation, Consignment Verification, and Lot Release of Medical Products (2026) aimed at strengthening regulatory oversight and ensuring that only safe, effective, and quality-assured medical products enter the Bhutanese market. The guideline introduces an integrated regulatory framework covering three major areas: Import Authorization, Consignment Verification, and Vaccine Lot Release. It establishes a structured approach to monitor products entering the country and to reduce risks associated with substandard, falsified, or unauthorized medical products.
A notable aspect of the draft is the adoption of a risk-based inspection model, where verification intensity is determined by factors such as product category, public health importance, compliance history, and previous quality issues.The guideline also highlights the use of modern screening approaches, including Raman spectrophotometry and mini-lab testing, to assess product identity and detect potential quality concerns before market release.
Additionally, vaccines will undergo mandatory lot release procedures, ensuring each imported lot meets regulatory requirements before distribution or use.
This initiative reflects Bhutan’s continued focus on strengthening supply chain integrity and aligning regulatory practices with evolving international standards.
KEYWORDS: Import Authorization, Drug Safety, Risk-Based Inspection
REFERENCE: https://bfda.gov.bt/public-consultation-for-guideline-on-importation-consignment-verification-and-lot-release-of-medical-product-2026/